<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36618714</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2731-4383</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>1</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Discover mental health</Title><ISOAbbreviation>Discov Ment Health</ISOAbbreviation></Journal><ArticleTitle>Fluoxetine plus lithium for treatment of mental health impairment in Long Covid.</ArticleTitle><Pagination><StartPage>1</StartPage><MedlinePgn>1</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1007/s44192-022-00027-w</ELocationID><Abstract><AbstractText Label="PURPOSES" NlmCategory="UNASSIGNED">(1) To summarize the mental conditions that may accompany persistent symptoms following acute infection by SARS-CoV-2, often termed Long Covid; (2) to formulate treatment based upon the brain cells that are dominantly affected.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">(1) Review the reports relating to the mental symptoms occurring in Long Covid. (2) Review the drugs that address the brain cells affected in Long Covid, and suggest pharmacotherapy for those patients whose response to psychotherapy is suboptimal.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Long Covid affects&#x2009;~&#x2009;10% of patients infected by SARS-CoV-2, and mental symptoms affect&#x2009;~&#x2009;20% of persons with Long Covid. The brain cell-types that have been demonstrated as dominantly affected in Long Covid are astrocytes, oligodendrocytes, neurons, endothelial cells/pericytes, and microglia. Lithium and fluoxetine each address all of those four cell-types. Low dosage of each is likely to be well-tolerated and to cause neither clinically important adverse events (AE) nor serious adverse events (SAE).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">For those patients whose response to psychotherapy is suboptimal, lithium and fluoxetine should be administered in combination for both depth of benefit and reduction of dosages.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fessel</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6772-3348</Identifier><AffiliationInfo><Affiliation>Department of Medicine, University of California, 2069 Filbert Street, San Francisco, CA 94123 USA.</Affiliation><Identifier Source="GRID">grid.266102.1</Identifier><Identifier Source="ISNI">0000 0001 2297 6811</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Discov Ment Health</MedlineTA><NlmUniqueID>9918350483906676</NlmUniqueID><ISSNLinking>2731-4383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Fluoxetine lithium</Keyword><Keyword MajorTopicYN="N">Long Covid</Keyword><Keyword MajorTopicYN="N">Mental symptoms</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Treatment</Keyword></KeywordList><CoiStatement>Competing interestsThe authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>9</Day><Hour>3</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>10</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36618714</ArticleId><ArticleId IdType="pmc">PMC9810252</ArticleId><ArticleId IdType="doi">10.1007/s44192-022-00027-w</ArticleId><ArticleId IdType="pii">27</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post COVID-19 condition or Long COVID: a meta-analysis and systematic review. J Infect Dis. 2022 doi: 10.1093/infdis/jiac136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac136</ArticleId><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M, Manoharan L, Elkheir N, et al. Characterising long COVID: a living systematic review. BMJ Glob Health. 2021;6(9):e005427. doi: 10.1136/bmjgh-2021-005427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2021-005427</ArticleId><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D, Sun A, Ssentongo AE, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open. 2021;4(10):e2128568. doi: 10.1001/jamanetworkopen.2021.28568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran V-T, Porcher R, Pane I, Ravaud P. Course of post COVID-19 disease symptoms over time in the ComPaRe long COVID prospective e-cohort. Nat Commun. 2022;13(1):1&#x2013;6. doi: 10.1038/s41467-022-29513-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-29513-z</ArticleId><ArticleId IdType="pmc">PMC8983754</ArticleId><ArticleId IdType="pubmed">35383197</ArticleId></ArticleIdList></Reference><Reference><Citation>Premraj L, Kannapadi NV, Briggs J, et al. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: a meta-analysis. J Neurol Sci. 2022;434:120162. doi: 10.1016/j.jns.2022.120162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2022.120162</ArticleId><ArticleId IdType="pmc">PMC8798975</ArticleId><ArticleId IdType="pubmed">35121209</ArticleId></ArticleIdList></Reference><Reference><Citation>Titze-de-Almeida R, da Cunha TR, dos Santos Silva LD, et al. Persistent, new-onset symptoms and mental health complaints in Long COVID in a Brazilian cohort of non-hospitalized patients. BMC Infect Dis. 2022;22(1):1&#x2013;11. doi: 10.1186/s12879-022-07065-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07065-3</ArticleId><ArticleId IdType="pmc">PMC8821794</ArticleId><ArticleId IdType="pubmed">35135496</ArticleId></ArticleIdList></Reference><Reference><Citation>Schandl A, Hedman A, Lyng&#xe5; P, et al. Long-term consequences in critically ill COVID-19 patients: a prospective cohort study. Acta Anaesthesiol Scand. 2021;65(9):1285&#x2013;1292. doi: 10.1111/aas.13939.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aas.13939</ArticleId><ArticleId IdType="pmc">PMC8212104</ArticleId><ArticleId IdType="pubmed">34097753</ArticleId></ArticleIdList></Reference><Reference><Citation>See&#xdf;le J, Waterboer T, Hippchen T, et al. Persistent symptoms in adult patients 1 year after coronavirus disease 2019 (COVID-19): a prospective cohort study. Clin Infect Dis. 2022;74(7):1191&#x2013;1198. doi: 10.1093/cid/ciab611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab611</ArticleId><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Kim S-W, Chang H-H, Kwon KT, Bae S, Hwang S. Post-acute COVID-19 syndrome in patients after 12 months from COVID-19 infection in Korea. BMC Infect Dis. 2022;22(1):1&#x2013;12. doi: 10.1186/s12879-022-07062-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07062-6</ArticleId><ArticleId IdType="pmc">PMC8793328</ArticleId><ArticleId IdType="pubmed">35086489</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrigues E, Janvier P, Kherabi Y, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020;81(6):e4&#x2013;e6. doi: 10.1016/j.jinf.2020.08.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.08.029</ArticleId><ArticleId IdType="pmc">PMC7445491</ArticleId><ArticleId IdType="pubmed">32853602</ArticleId></ArticleIdList></Reference><Reference><Citation>Houben-Wilke S, Go&#xeb;rtz YM, Delbressine JM, et al. The impact of long COVID-19 on mental health: observational 6-month follow-up study. JMIR Ment health. 2022;9(2):e33704. doi: 10.2196/33704.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/33704</ArticleId><ArticleId IdType="pmc">PMC8914795</ArticleId><ArticleId IdType="pubmed">35200155</ArticleId></ArticleIdList></Reference><Reference><Citation>Badenoch JB, Rengasamy ER, Watson C, et al. Persistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysis. Brain Commun. 2022;4(1):fcab297. doi: 10.1093/braincomms/fcab297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcab297</ArticleId><ArticleId IdType="pmc">PMC8833580</ArticleId><ArticleId IdType="pubmed">35169700</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Yao Q, Gu X, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet. 2021;398(10302):747&#x2013;758. doi: 10.1016/S0140-6736(21)01755-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01755-4</ArticleId><ArticleId IdType="pmc">PMC8389999</ArticleId><ArticleId IdType="pubmed">34454673</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban F, Ling S, Lui LM, et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: a systematic review and meta-analysis. Brain Behav Immun. 2022;101:93&#x2013;135. doi: 10.1016/j.bbi.2021.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.12.020</ArticleId><ArticleId IdType="pmc">PMC8715665</ArticleId><ArticleId IdType="pubmed">34973396</ArticleId></ArticleIdList></Reference><Reference><Citation>Frontera JA, Yang D, Lewis A, et al. A prospective study of long-term outcomes among hospitalized COVID-19 patients with and without neurological complications. J Neurol Sci. 2021;426:117486. doi: 10.1016/j.jns.2021.117486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2021.117486</ArticleId><ArticleId IdType="pmc">PMC8113108</ArticleId><ArticleId IdType="pubmed">34000678</ArticleId></ArticleIdList></Reference><Reference><Citation>McGirr A, Nathan S, Ghahremani M, Gill S, Smith EE, Ismail Z. Progression to dementia or reversion to normal cognition in mild cognitive impairment as a function of late-onset neuropsychiatric symptoms. Neurology. 2022;98(21):e2132&#x2013;e2139. doi: 10.1212/WNL.0000000000200256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000200256</ArticleId><ArticleId IdType="pmc">PMC9169943</ArticleId><ArticleId IdType="pubmed">35351783</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry. 2021;8(2):130&#x2013;140. doi: 10.1016/S2215-0366(20)30462-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(20)30462-4</ArticleId><ArticleId IdType="pmc">PMC7820108</ArticleId><ArticleId IdType="pubmed">33181098</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Zhang M, Garcia G, Jr, et al. ApoE-isoform-dependent SARS-CoV-2 neurotropism and cellular response. Cell Stem Cell. 2021;28(2):331&#x2013;42. e5. doi: 10.1016/j.stem.2020.12.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2020.12.018</ArticleId><ArticleId IdType="pmc">PMC7832490</ArticleId><ArticleId IdType="pubmed">33450186</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostendorf BN, Patel MA, Bilanovic J, et al. Common human genetic variants of APOE impact murine COVID-19 mortality. Nature. 2022;611(7935):346&#x2013;351. doi: 10.1038/s41586-022-05344-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05344-2</ArticleId><ArticleId IdType="pmc">PMC10957240</ArticleId><ArticleId IdType="pubmed">36130725</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Xu J, Hou Y, et al. Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment. Alzheimers Res Ther. 2021;13(1):1&#x2013;19. doi: 10.1186/s13195-021-00850-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-021-00850-3</ArticleId><ArticleId IdType="pmc">PMC8189279</ArticleId><ArticleId IdType="pubmed">34108016</ArticleId></ArticleIdList></Reference><Reference><Citation>Maiese A, Manetti AC, Bosetti C, et al. SARS-CoV-2 and the brain: a review of the current knowledge on neuropathology in COVID-19. Brain Pathol. 2021;31(6):e13013. doi: 10.1111/bpa.13013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.13013</ArticleId><ArticleId IdType="pmc">PMC8420197</ArticleId><ArticleId IdType="pubmed">34390282</ArticleId></ArticleIdList></Reference><Reference><Citation>Renaud-Charest O, Lui LM, Eskander S, et al. Onset and frequency of depression in post-COVID-19 syndrome: a systematic review. J Psychiatr Res. 2021;144:129&#x2013;137. doi: 10.1016/j.jpsychires.2021.09.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychires.2021.09.054</ArticleId><ArticleId IdType="pmc">PMC8482840</ArticleId><ArticleId IdType="pubmed">34619491</ArticleId></ArticleIdList></Reference><Reference><Citation>Janiri D, Carf&#xec; A, Kotzalidis GD, et al. Posttraumatic stress disorder in patients after severe COVID-19 infection. JAMA Psychiatry. 2021;78(5):567&#x2013;569. doi: 10.1001/jamapsychiatry.2021.0109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2021.0109</ArticleId><ArticleId IdType="pmc">PMC7893542</ArticleId><ArticleId IdType="pubmed">33599709</ArticleId></ArticleIdList></Reference><Reference><Citation>Crunfli F, Carregari VC, Veras FP, et al. SARS-CoV-2 infects brain astrocytes of COVID-19 patients and impairs neuronal viability. MedRxiv. 2021 doi: 10.1101/2020.10.09.20207464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.10.09.20207464</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews MG, Mukhtar T, Eze UC, et al. Tropism of SARS-CoV-2 for human cortical astrocytes. Proc Natl Acad Sci. 2022;119(30):e2122236119. doi: 10.1073/pnas.2122236119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2122236119</ArticleId><ArticleId IdType="pmc">PMC9335272</ArticleId><ArticleId IdType="pubmed">35858406</ArticleId></ArticleIdList></Reference><Reference><Citation>Song E, Zhang C, Israelow B, et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J Exp Med. 2021;218(3):e20202135. doi: 10.1084/jem.20202135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20202135</ArticleId><ArticleId IdType="pmc">PMC7808299</ArticleId><ArticleId IdType="pubmed">33433624</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R, Wang K, Yu J, et al. The spatial and cell-type distribution of SARS-CoV-2 receptor ACE2 in the human and mouse brains. Front Neurol. 2021;11:573095. doi: 10.3389/fneur.2020.573095.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.573095</ArticleId><ArticleId IdType="pmc">PMC7855591</ArticleId><ArticleId IdType="pubmed">33551947</ArticleId></ArticleIdList></Reference><Reference><Citation>Strafella C, Caputo V, Termine A, et al. Analysis of ACE2 genetic variability among populations highlights a possible link with COVID-19-related neurological complications. Genes. 2020;11(7):741. doi: 10.3390/genes11070741.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes11070741</ArticleId><ArticleId IdType="pmc">PMC7397291</ArticleId><ArticleId IdType="pubmed">32635188</ArticleId></ArticleIdList></Reference><Reference><Citation>Young BE, Ong SW, Ng LF, et al. Viral dynamics and immune correlates of coronavirus disease 2019 (COVID-19) severity. Clin Infect Dis. 2021;73(9):e2932&#x2013;e2942. doi: 10.1093/cid/ciaa1280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1280</ArticleId><ArticleId IdType="pmc">PMC7499509</ArticleId><ArticleId IdType="pubmed">32856707</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwabenland M, Sali&#xe9; H, Tanevski J, et al. Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions. Immunity. 2021;54(7):1594&#x2013;610. e11. doi: 10.1016/j.immuni.2021.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.06.002</ArticleId><ArticleId IdType="pmc">PMC8188302</ArticleId><ArticleId IdType="pubmed">34174183</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzano GS, McEntire CR, Martinez-Lage M, Mateen FJ, Hutto SK. Acute disseminated encephalomyelitis and acute hemorrhagic leukoencephalitis following COVID-19: systematic review and meta-synthesis. Neurol Neuroimmunol Neuroinflamm. 2021;8(6):e1080. doi: 10.1212/NXI.0000000000001080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000001080</ArticleId><ArticleId IdType="pmc">PMC8404207</ArticleId><ArticleId IdType="pubmed">34452974</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang EY, Mao T, Klein J, et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595:283&#x2013;288. doi: 10.1038/s41586-021-03631-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03631-y</ArticleId><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Ide T, Kawanami T, Eriguchi M, Hara H. SARS-CoV-2-related myelin oligodendrocyte glycoprotein antibody-associated disease: a case report and literature review. Intern Med. 2022;61:8709&#x2013;8721. doi: 10.2169/internalmedicine.8709-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.8709-21</ArticleId><ArticleId IdType="pmc">PMC9107978</ArticleId><ArticleId IdType="pubmed">35135920</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan M, Yoo SJ, Clijsters M, et al. Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb. Cell. 2021;184(24):5932&#x2013;49. e15. doi: 10.1016/j.cell.2021.10.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.10.027</ArticleId><ArticleId IdType="pmc">PMC8564600</ArticleId><ArticleId IdType="pubmed">34798069</ArticleId></ArticleIdList></Reference><Reference><Citation>Matschke J, L&#xfc;tgehetmann M, Hagel C, et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. 2020;19(11):919&#x2013;929. doi: 10.1016/S1474-4422(20)30308-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30308-2</ArticleId><ArticleId IdType="pmc">PMC7535629</ArticleId><ArticleId IdType="pubmed">33031735</ArticleId></ArticleIdList></Reference><Reference><Citation>Paniz-Mondolfi A, Bryce C, Grimes Z, et al. Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) J Med Virol. 2020;92(7):699&#x2013;702. doi: 10.1002/jmv.25915.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25915</ArticleId><ArticleId IdType="pmc">PMC7264598</ArticleId><ArticleId IdType="pubmed">32314810</ArticleId></ArticleIdList></Reference><Reference><Citation>Charnley M, Islam S, Bindra GK, et al. Neurotoxic amyloidogenic peptides in the proteome of SARS-COV2: potential implications for neurological symptoms in COVID-19. Nat Commun. 2022;13(1):1&#x2013;11. doi: 10.1038/s41467-022-30932-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30932-1</ArticleId><ArticleId IdType="pmc">PMC9189797</ArticleId><ArticleId IdType="pubmed">35697699</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapogiannis D, Mattson MP. Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease. Lancet Neurol. 2011;10(2):187&#x2013;198. doi: 10.1016/S1474-4422(10)70277-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70277-5</ArticleId><ArticleId IdType="pmc">PMC3026092</ArticleId><ArticleId IdType="pubmed">21147038</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirschenbaum D, Imbach LL, Rushing EJ, et al. Intracerebral endotheliitis and microbleeds are neuropathological features of COVID-19. Neuropathol Appl Neurobiol. 2021;47(3):454&#x2013;459. doi: 10.1111/nan.12677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12677</ArticleId><ArticleId IdType="pmc">PMC7753688</ArticleId><ArticleId IdType="pubmed">33249605</ArticleId></ArticleIdList></Reference><Reference><Citation>Taha M, Samavati L. Antiphospholipid antibodies in COVID-19: a meta-analysis and systematic review. RMD Open. 2021;7(2):e001580. doi: 10.1136/rmdopen-2021-001580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2021-001580</ArticleId><ArticleId IdType="pmc">PMC8103564</ArticleId><ArticleId IdType="pubmed">33958439</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Papa N, Guidali L, Spatola L, et al. Relationship between anti-phospholipid and anti-endothelial cell antibodies III: beta 2 glycoprotein I mediates the antibody binding to endothelial membranes and induces the expression of adhesion molecules. Clin Exp Rheumatol. 1995;13(2):179&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">7544710</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi H, Zuo Y, Navaz S, et al. Endothelial cell-activating antibodies in COVID-19. Arthritis &amp; Rheumatology. 2022;74(7):1132&#x2013;1138. doi: 10.1002/art.42094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42094</ArticleId><ArticleId IdType="pmc">PMC9082472</ArticleId><ArticleId IdType="pubmed">35174669</ArticleId></ArticleIdList></Reference><Reference><Citation>Bocci M, Oudenaarden C, S&#xe0;enz-Sard&#xe0; X, et al. Infection of brain pericytes underlying neuropathology of COVID-19 patients. Int J Mol Sci. 2021;22(21):11622. doi: 10.3390/ijms222111622.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222111622</ArticleId><ArticleId IdType="pmc">PMC8583965</ArticleId><ArticleId IdType="pubmed">34769052</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirunpattarasilp C, James G, Kwanthongdee J, et al. SARS-CoV-2 triggers pericyte-mediated cerebral capillary constriction. Brain. 2022 doi: 10.1093/brain/awac272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac272</ArticleId><ArticleId IdType="pmc">PMC9384509</ArticleId><ArticleId IdType="pubmed">35867861</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakur KT, Miller EH, Glendinning MD, et al. COVID-19 neuropathology at columbia university irving medical center/New York presbyterian hospital. Brain. 2021;144(9):2696&#x2013;2708. doi: 10.1093/brain/awab148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab148</ArticleId><ArticleId IdType="pmc">PMC8083258</ArticleId><ArticleId IdType="pubmed">33856027</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivera AD, Butt AM. Astrocytes are direct cellular targets of lithium treatment: novel roles for lysyl oxidase and peroxisome-proliferator activated receptor-&#x3b3; as astroglial targets of lithium. Transl Psychiatry. 2019;9(1):1&#x2013;14. doi: 10.1038/s41398-019-0542-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-019-0542-2</ArticleId><ArticleId IdType="pmc">PMC6718419</ArticleId><ArticleId IdType="pubmed">31477687</ArticleId></ArticleIdList></Reference><Reference><Citation>Meffre D, Massaad C, Grenier J. Lithium chloride stimulates PLP and MBP expression in oligodendrocytes via Wnt/&#x3b2;-catenin and Akt/CREB pathways. Neuroscience. 2015;284:962&#x2013;971. doi: 10.1016/j.neuroscience.2014.10.064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2014.10.064</ArticleId><ArticleId IdType="pubmed">25451297</ArticleId></ArticleIdList></Reference><Reference><Citation>Emamghoreishi M, Keshavarz M, Nekooeian AA. Acute and chronic effects of lithium on BDNF and GDNF mRNA and protein levels in rat primary neuronal, astroglial and neuroastroglia cultures. Iran J Basic Med Sci. 2015;18(3):240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4414989</ArticleId><ArticleId IdType="pubmed">25945236</ArticleId></ArticleIdList></Reference><Reference><Citation>Son H, Yu IT, Hwang SJ, et al. Lithium enhances long-term potentiation independently of hippocampal neurogenesis in the rat dentate gyrus. J Neurochem. 2003;85(4):872&#x2013;881. doi: 10.1046/j.1471-4159.2003.01725.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2003.01725.x</ArticleId><ArticleId IdType="pubmed">12716419</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK. Enhancement of hippocampal neurogenesis by lithium. J Neurochem. 2000;75(4):1729&#x2013;1734. doi: 10.1046/j.1471-4159.2000.0751729.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2000.0751729.x</ArticleId><ArticleId IdType="pubmed">10987856</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiorentini A, Rosi MC, Grossi C, Luccarini I, Casamenti F. Lithium improves hippocampal neurogenesis, neuropathology and cognitive functions in APP mutant mice. PLoS ONE. 2010;5(12):e14382. doi: 10.1371/journal.pone.0014382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0014382</ArticleId><ArticleId IdType="pmc">PMC3004858</ArticleId><ArticleId IdType="pubmed">21187954</ArticleId></ArticleIdList></Reference><Reference><Citation>Dwivedi T, Zhang H. Lithium-induced neuroprotection is associated with epigenetic modification of specific BDNF gene promoter and altered expression of apoptotic-regulatory proteins. Front Neurosci. 2015;8:457. doi: 10.3389/fnins.2014.00457.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2014.00457</ArticleId><ArticleId IdType="pmc">PMC4294125</ArticleId><ArticleId IdType="pubmed">25642163</ArticleId></ArticleIdList></Reference><Reference><Citation>Fornai F, Longone P, Cafaro L, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci. 2008;105(6):2052&#x2013;2057. doi: 10.1073/pnas.0708022105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0708022105</ArticleId><ArticleId IdType="pmc">PMC2538879</ArticleId><ArticleId IdType="pubmed">18250315</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerr F, Bjedov I, Sofola-Adesakin O. Molecular mechanisms of lithium action: switching the light on multiple targets for dementia using animal models. Front Mol Neurosci. 2018 doi: 10.3389/fnmol.2018.00297.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2018.00297</ArticleId><ArticleId IdType="pmc">PMC6121012</ArticleId><ArticleId IdType="pubmed">30210290</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurer IC, Schippel P, Volz HP. Lithium-induced enhancement of mitochondrial oxidative phosphorylation in human brain tissue. Bipolar Disord. 2009;11(5):515&#x2013;522. doi: 10.1111/j.1399-5618.2009.00729.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-5618.2009.00729.x</ArticleId><ArticleId IdType="pubmed">19624390</ArticleId></ArticleIdList></Reference><Reference><Citation>Shalbuyeva N, Brustovetsky T, Brustovetsky N. Lithium desensitizes brain mitochondria to calcium, antagonizes permeability transition, and diminishes cytochrome C release. J Biol Chem. 2007;282(25):18057&#x2013;18068. doi: 10.1074/jbc.M702134200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M702134200</ArticleId><ArticleId IdType="pubmed">17485418</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji Y-B, Gao Q, Tan X-X, et al. Lithium alleviates blood-brain barrier breakdown after cerebral ischemia and reperfusion by upregulating endothelial Wnt/&#x3b2;-catenin signaling in mice. Neuropharmacology. 2021;186:108474. doi: 10.1016/j.neuropharm.2021.108474.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2021.108474</ArticleId><ArticleId IdType="pubmed">33524408</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeilbeck LF, M&#xfc;ller B, Knobloch V, Tamm ER, Ohlmann A. Differential angiogenic properties of lithium chloride in vitro and in vivo. PLoS ONE. 2014;9(4):e95546. doi: 10.1371/journal.pone.0095546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0095546</ArticleId><ArticleId IdType="pmc">PMC3994089</ArticleId><ArticleId IdType="pubmed">24751879</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong H, Zhang X, Dai X, et al. Lithium ameliorates lipopolysaccharide-induced microglial activation via inhibition of toll-like receptor 4 expression by activating the PI3K/Akt/FoxO1 pathway. J Neuroinflammation. 2014;11(1):140. doi: 10.1186/s12974-014-0140-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-014-0140-4</ArticleId><ArticleId IdType="pmc">PMC4149204</ArticleId><ArticleId IdType="pubmed">25115727</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuskaitis CJ, Jope RS. Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity. Cell Signal. 2009;21(2):264&#x2013;273. doi: 10.1016/j.cellsig.2008.10.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2008.10.014</ArticleId><ArticleId IdType="pmc">PMC2630396</ArticleId><ArticleId IdType="pubmed">19007880</ArticleId></ArticleIdList></Reference><Reference><Citation>Davenport CM, Sevastou IG, Hooper C, Pocock JM. Inhibiting p53 pathways in microglia attenuates microglial-evoked neurotoxicity following exposure to Alzheimer peptides. J Neurochem. 2010;112(2):552&#x2013;563. doi: 10.1111/j.1471-4159.2009.06485.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.06485.x</ArticleId><ArticleId IdType="pubmed">19895660</ArticleId></ArticleIdList></Reference><Reference><Citation>Fourgeaud L, Boulanger LM. Synapse remodeling, compliments of the complement system. Cell. 2007;131(6):1034&#x2013;1036. doi: 10.1016/j.cell.2007.11.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.11.031</ArticleId><ArticleId IdType="pubmed">18083091</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Z, Ono C, Aiba S, et al. Therapeutic concentration of lithium stimulates complement C 3 production in dendritic cells and microglia via GSK-3 inhibition. Glia. 2015;63(2):257&#x2013;270. doi: 10.1002/glia.22749.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22749</ArticleId><ArticleId IdType="pubmed">25179772</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinoshita M, Hirayama Y, Fujishita K, et al. Anti-depressant fluoxetine reveals its therapeutic effect via astrocytes. EBioMedicine. 2018;32:72&#x2013;83. doi: 10.1016/j.ebiom.2018.05.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2018.05.036</ArticleId><ArticleId IdType="pmc">PMC6020856</ArticleId><ArticleId IdType="pubmed">29887330</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JY, Kang SR, Yune TY. Fluoxetine prevents oligodendrocyte cell death by inhibiting microglia activation after spinal cord injury. J Neurotrauma. 2015;32(9):633&#x2013;644. doi: 10.1089/neu.2014.3527.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.2014.3527</ArticleId><ArticleId IdType="pmc">PMC4410451</ArticleId><ArticleId IdType="pubmed">25366938</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Luo Y, Tang J, et al. The effects of fluoxetine on oligodendrocytes in the hippocampus of chronic unpredictable stress-induced depressed model rats. J Comp Neurol. 2020;528(15):2583&#x2013;2594. doi: 10.1002/cne.24914.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.24914</ArticleId><ArticleId IdType="pubmed">32246847</ArticleId></ArticleIdList></Reference><Reference><Citation>Cz&#xe9;h B, M&#xfc;ller-Keuker JI, Rygula R, et al. Chronic social stress inhibits cell proliferation in the adult medial prefrontal cortex: hemispheric asymmetry and reversal by fluoxetine treatment. Neuropsychopharmacology. 2007;32(7):1490&#x2013;1503. doi: 10.1038/sj.npp.1301275.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.npp.1301275</ArticleId><ArticleId IdType="pubmed">17164819</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianchi M, Shah AJ, Fone KC, et al. Fluoxetine administration modulates the cytoskeletal microtubular system in the rat hippocampus. Synapse. 2009;63(4):359&#x2013;364. doi: 10.1002/syn.20614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/syn.20614</ArticleId><ArticleId IdType="pubmed">19140168</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanisavljevi&#x107; A, Peri&#x107; I, Gass P, et al. Fluoxetine modulates neuronal activity in stress-related limbic areas of adult rats subjected to the chronic social isolation. Brain Res Bull. 2020;163:95&#x2013;108. doi: 10.1016/j.brainresbull.2020.07.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2020.07.021</ArticleId><ArticleId IdType="pubmed">32730865</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Gao Y, Jiang L, et al. Fluoxetine attenuates the impairment of spatial learning ability and prevents neuron loss in middle-aged APPswe/PSEN1dE9 double transgenic Alzheimer's disease mice. Oncotarget. 2017;8(17):27676. doi: 10.18632/oncotarget.15398.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.15398</ArticleId><ArticleId IdType="pmc">PMC5438600</ArticleId><ArticleId IdType="pubmed">28430602</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y, Yao Y, Liang X, et al. Changes in white matter and the effects of fluoxetine on such changes in the CUS rat model of depression. Neurosci Lett. 2019;694:104&#x2013;110. doi: 10.1016/j.neulet.2018.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2018.11.013</ArticleId><ArticleId IdType="pubmed">30423401</ArticleId></ArticleIdList></Reference><Reference><Citation>Ofek K, Schoknecht K, Melamed-Book N, Heinemann U, Friedman A, Soreq H. Fluoxetine induces vasodilatation of cerebral arterioles by co-modulating NO/muscarinic signalling. J Cell Mol Med. 2012;16(11):2736&#x2013;2744. doi: 10.1111/j.1582-4934.2012.01596.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1582-4934.2012.01596.x</ArticleId><ArticleId IdType="pmc">PMC4118242</ArticleId><ArticleId IdType="pubmed">22697296</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, Kim SR, Park J-Y, et al. Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation. Neuropharmacology. 2011;60(6):963&#x2013;974. doi: 10.1016/j.neuropharm.2011.01.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2011.01.043</ArticleId><ArticleId IdType="pubmed">21288472</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F, Zhou H, Wilson BC, Shi J-S, Hong J-S, Gao H-M. Fluoxetine protects neurons against microglial activation-mediated neurotoxicity. Parkinsonism Relat Disord. 2012;18:S213&#x2013;S217. doi: 10.1016/S1353-8020(11)70066-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1353-8020(11)70066-9</ArticleId><ArticleId IdType="pmc">PMC3608679</ArticleId><ArticleId IdType="pubmed">22166439</ArticleId></ArticleIdList></Reference><Reference><Citation>Su F, Yi H, Xu L, Zhang Z. Fluoxetine and S-citalopram inhibit M1 activation and promote M2 activation of microglia in vitro. Neuroscience. 2015;294:60&#x2013;68. doi: 10.1016/j.neuroscience.2015.02.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2015.02.028</ArticleId><ArticleId IdType="pubmed">25711936</ArticleId></ArticleIdList></Reference><Reference><Citation>Grandjean EM, Aubry J-M. Lithium: updated human knowledge using an evidence-based approach. CNS Drugs. 2009;23(5):397&#x2013;418. doi: 10.2165/00023210-200923050-00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00023210-200923050-00004</ArticleId><ArticleId IdType="pubmed">19453201</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoot TS, Molmans TH, Grootens KP, Kerckhoffs AP. Systematic review and practical guideline for the prevention and management of the renal side effects of lithium therapy. Eur Neuropsychopharmacol. 2020;31:16&#x2013;32. doi: 10.1016/j.euroneuro.2019.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euroneuro.2019.11.006</ArticleId><ArticleId IdType="pubmed">31837914</ArticleId></ArticleIdList></Reference><Reference><Citation>Beasley CM, Jr, Koke SC, Nilsson ME, Gonzales JS. Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis. Clin Ther. 2000;22(11):1319&#x2013;1330. doi: 10.1016/S0149-2918(00)83028-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0149-2918(00)83028-3</ArticleId><ArticleId IdType="pubmed">11117656</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodbridge J, Townsend M, Reis S, Singh S, Grenyer BF. Non-response to psychotherapy for borderline personality disorder: a systematic review. Aust NZ J Psychiatry. 2022;56(7):771&#x2013;787. doi: 10.1177/00048674211046893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/00048674211046893</ArticleId><ArticleId IdType="pmc">PMC9218414</ArticleId><ArticleId IdType="pubmed">34525867</ArticleId></ArticleIdList></Reference><Reference><Citation>Seligman ME. The effectiveness of psychotherapy: the consumer reports study. Am Psychol. 1995;50(12):965. doi: 10.1037/0003-066X.50.12.965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/0003-066X.50.12.965</ArticleId><ArticleId IdType="pubmed">8561380</ArticleId></ArticleIdList></Reference><Reference><Citation>Romanelli RJ, Wu FM, Gamba R, Mojtabai R, Segal JB. Behavioral therapy and serotonin reuptake inhibitor pharmacotherapy in the treatment of obsessive&#x2013;compulsive disorder: a systematic review and meta-analysis of head-to-head randomized controlled trials. Depress Anxiety. 2014;31(8):641&#x2013;652. doi: 10.1002/da.22232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/da.22232</ArticleId><ArticleId IdType="pubmed">24390912</ArticleId></ArticleIdList></Reference><Reference><Citation>Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry. 2011;198(5):351&#x2013;356. doi: 10.1192/bjp.bp.110.080044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.bp.110.080044</ArticleId><ArticleId IdType="pubmed">21525519</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer M, Linden M, Schaaf B, Weber HJ. Adverse events and tolerability of the combination of fluoxetine/lithium compared with fluoxetine. J Clin Psychopharmacol. 1996;16(2):130&#x2013;134. doi: 10.1097/00004714-199604000-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00004714-199604000-00005</ArticleId><ArticleId IdType="pubmed">8690828</ArticleId></ArticleIdList></Reference><Reference><Citation>Fava M, Alpert J, Nierenberg A, et al. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol. 2002;22(4):379&#x2013;387. doi: 10.1097/00004714-200208000-00008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00004714-200208000-00008</ArticleId><ArticleId IdType="pubmed">12172337</ArticleId></ArticleIdList></Reference><Reference><Citation>Pessoa L. Emergent processes in cognitive-emotional interactions. Dialogues Clin Neurosci. 2022 doi: 10.31887/DCNS.2010.12.4/lpessoa.</Citation><ArticleIdList><ArticleId IdType="doi">10.31887/DCNS.2010.12.4/lpessoa</ArticleId><ArticleId IdType="pmc">PMC3117594</ArticleId><ArticleId IdType="pubmed">21319489</ArticleId></ArticleIdList></Reference><Reference><Citation>Krubitzer L. In search of a unifying theory of complex brain evolution. Ann NY Acad Sci. 2009;1156(1):44&#x2013;67. doi: 10.1111/j.1749-6632.2009.04421.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2009.04421.x</ArticleId><ArticleId IdType="pmc">PMC2666944</ArticleId><ArticleId IdType="pubmed">19338502</ArticleId></ArticleIdList></Reference><Reference><Citation>Baranova A, Cao H, Teng S, Zhang F. A phenome-wide investigation of risk factors for severe COVID-19. J Med Virol. 2022 doi: 10.1002/jmv.28264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28264</ArticleId><ArticleId IdType="pmc">PMC9874597</ArticleId><ArticleId IdType="pubmed">36316288</ArticleId></ArticleIdList></Reference><Reference><Citation>Baranova A, Cao H, Zhang F. Severe COVID-19 increases the risk of schizophrenia. Psychiatry Res. 2022;317:114809. doi: 10.1016/j.psychres.2022.114809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psychres.2022.114809</ArticleId><ArticleId IdType="pmc">PMC9398553</ArticleId><ArticleId IdType="pubmed">36037742</ArticleId></ArticleIdList></Reference><Reference><Citation>Baranova A, Cao H, Zhang F. Causal effect of COVID-19 on Alzheimer's disease: a Mendelian randomization study. J Med Virol. 2022 doi: 10.1002/jmv.28107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28107</ArticleId><ArticleId IdType="pmc">PMC9539282</ArticleId><ArticleId IdType="pubmed">36039844</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>